The Role of PPAR-gamma C161T Polymorphism in Colorectal Cancer Susceptibility

In Vivo. 2022 Jul-Aug;36(4):1911-1915. doi: 10.21873/invivo.12911.

Abstract

Background/aim: This study aimed to determine the role of the peroxisome proliferator-activated receptor-gamma (PPARg) C161T genotype and allele frequencies in predisposition to colorectal cancer (CRC).

Patients and methods: PPARg C161T (His447His; rs3856806) gene polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism analysis in patients with CRC (n=101) and controls (n=238).

Results: The T161 allele (CT+TT genotypes) of PPARg C161T polymorphism was associated with CRC development (p<0.001; OR=3.239, 95%CI=1.997-5.252). Subgroup analysis showed that the T161 allele was associated with a 3.056-fold increased risk for colon cancer (CC) (p<0.001; 95%CI=1.709-5.464) and 3.529-fold increased risk for rectal cancer (RC) (p<0.001; 95%C=1.784-6.981). Frequencies of the T161 allele were also higher in total CRC and CC patients with poorly differentiated tumors (p<0.001, c2=30,601, OR=3.109; 95%CI=1.970-4.906 and p<0.001, Fisher exact test, respectively).

Conclusion: PPARg T161 allele carriers have increased risk for developing CRC.

Keywords: PPARg C161T polymorphism; Turkish population; colorectal cancer.

MeSH terms

  • Alleles
  • Case-Control Studies
  • Colorectal Neoplasms* / genetics
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • PPAR gamma* / genetics
  • Polymorphism, Single Nucleotide

Substances

  • PPAR gamma
  • PPARG protein, human